The locomotor-reducing effects of GABAergic drugs do not depend on the GABAA receptor

Increased MMP-9 levels with strain-dependent stress resilience and tunnel handling in mice

Increased perineuronal net (PNN) deposition has been observed in association with corticosteroid administration and stress in rodent models of depression. PNNs are a specialized form of extracellular matrix (ECM) that may enhance GABA-mediated inhibitory neurotransmission to potentially restrict the excitation and plasticity of pyramidal glutamatergic neurons. In contrast, antidepressant administration increases levels of the PNN-degrading enzyme matrix metalloproteinase-9 (MMP-9), which enhances glutamatergic plasticity and neurotransmission. In the present study, we compare pro-MMP-9 levels and measures of stress in females from two mouse strains, C57BL/6 J and BALB/cJ, in the presence or absence of tail grasping versus tunnel-associated cage transfers. Prior work suggests that C57BL/6 J mice show relatively enhanced neuroplasticity and stress resilience, while BALB/c mice demonstrate enhanced susceptibility to adverse effects of stress. Herein we observe that as compared to the C57BL/6 J strain, BALB/c mice demonstrate a higher level of baseline anxiety as determined by elevated plus maze (EPM) testing. Moreover, as determined by open field testing, anxiety is differentially reduced in BALB/c mice by a choice-driven tunnel-entry cage transfer technique. Additionally, as compared to tail-handled C57BL/6 J mice, tail-handled BALB/c mice have reduced brain levels of pro-MMP-9 and increased levels of its endogenous inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1); however, tunnel-associated cage transfer increases pro-MMP-9 levels in BALB/c mice. BALB/c mice also show increases in Western blot immunoreactive bands for brevican, a constituent of PNNs. Together, these data support the possibility that MMP-9, an effector of PNN remodeling, contributes to the phenotype of strain and handling-associated differences in behavior.

The role of nucleus accumbens shell GABA receptors on ventral tegmental area intracranial self-stimulation and a potential role for the 5-HT(2C) receptor

Brain γ-aminobutyric acid (GABA) and 5-hydroxytryptamine (5-HT)(2C) receptors are implicated in the neuronal regulation of reward- and aversion-related behaviour. Within the mesocorticolimbic pathways of the brain, relationships between GABA containing neurons and 5-HT(2C) receptor activity may be important in this context. The primary aim of this study was to investigate the role of NAc shell GABA receptors on ventral tegmental area intracranial self-stimulation (ICSS) and to examine the systemic effects of GABAergic ligands in this context. The second aim was to investigate the relationship between GABA receptor- and 5-HT(2C) receptor-related ICSS behaviour, using systemic administration of the selective agonist WAY 161503. Locomotor activity was assessed to compare the potential motor effects of drugs; feeding behaviour and intra-NAc injections of amphetamine (1.0 µg/side) were used as positive controls. When administered systemically the GABA(A) receptor agonist muscimol and antagonist picrotoxin did not selectively change ICSS reward thresholds, although the 5-HT(2C) receptor agonist WAY 161503 (1.0 mg/kg) decreased reward measures. Intra-NAc shell administration of muscimol (225 ng/side) and picrotoxin (125 ng/side), respectively, decreased and increased measures of reward. Intra-NAc shell baclofen (0-225 ng/side; GABA(B) receptor agonist) did not affect any ICSS measures although it increased feeding. Combining picrotoxin and WAY 161503 attenuated the effects of each. These results suggest that a 5-HT(2C) and GABA(A) receptor-mediated neuronal relationship in the NAc shell may be relevant for the regulation of brain reward pathways.

Imaging addiction with PET: is insight in sight?

Neurochemical imaging studies can identify molecular targets of abused drugs and link them to the underlying pathology associated with behaviors such as drug dependence, addiction and withdrawal. positron emission tomography (PET) is opening new avenues for the investigation of the neurochemical disturbances underlying drug abuse and addiction and the in vivo mechanisms by which medications might ameliorate these conditions. PET can identify vulnerable human populations, treatment strategies and monitor treatment efficacy. Thus, with this tool and the knowledge it provides, the potential for developing novel drugs and treatment strategies for drug addiction is now close at hand.

GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings

A growing preclinical and clinical literature suggests that GABA(B) receptor agonists promote abstinence and reduce the use of cocaine, heroin, alcohol and nicotine. The purpose of this paper is to critically review these data. GABA(B) receptor agonists, such as baclofen, appear to reduce the reinforcing effects of abused drugs in animal models under multiple experimental procedures. This occurs at doses that have little effect on responding for other positive reinforcers such as food or water. We review evidence that these potential therapeutic effects may be mediated by modulation of mesolimbic dopamine neurons. This review also examines the preliminary clinical data from studies of the efficacy of baclofen for treatment of cocaine, alcohol, and nicotine dependence. We suggest that these preliminary data provide a rationale for conducting more systematic studies of the effects of GABA(B) receptor agonists as treatment for drug abuse. This line of research may also improve our understanding of the neurochemical mechanisms underlying the drug dependence process.

GABAergic drugs and sexual behaviour in the rabbit: evidence for species-specific effects

The effects of gamma-amino butyric acid (GABA)-ergic drugs on male rabbit sexual behaviour have been evaluated. The GABA(A) agonist 4,5,6,7-tetrahydroxixazolo-5,4c-pyridin-3-ol (THIP), the GABA(B) agonist R-baclofen and the GABA antagonists picrotoxin and bicuculline were used. Injection of THIP, 20 mg/kg, s.c. produced a complete suppression of sexual behaviour and R-baclofen, 2.5 mg/kg, s.c. a significant inhibition. Intraperitoneal injections produced effects at higher doses than did s.c. injections. The inhibition produced by R-baclofen was associated with strong motor effects as shown by the water escape test. It is probable, therefore, that the reduced sexual behaviour observed after treatment with this drug is a consequence of sedative or muscle relaxant effects. By contrast, the dose of THIP that inhibited sexual behaviour had no effect on the water escape test. These results show that the GABA(A) agonist inhibits sexual behaviour in the male rabbit independent of effects on the motor system. The GABA antagonists had marginal or no effects on sexual behaviour. When these data are compared to previous results in the rat, substantial differences are seen. As there are differences between the effects on rat and rabbit sexual behaviour by other types of drugs, it appears that drug action on sexual behaviour cannot be generalized from one species to another.

GABAergic drugs inhibit amphetamine-induced distractibility in the rat

Drugs facilitating GABAergic neurotransmission have been reported to block some behavioral actions of dopaminergic stimulation but not others. The present experiments were performed with the purpose to extend the range of behaviors in which the interaction between GABA and dopamine have been studied. The ability of the GABAB agonist baclofen and the GABA transaminase inhibitor sodium valproate to block the enhanced distractibility produced by amphetamine was evaluated in a procedure especially designed for analyzing drugs' effects on distractibility. Briefly, rats were trained to traverse a straight runway with a sucrose solution as reinforcement. Once the response had been acquired, an additional runway ending in an empty box was connected. The time spent investigating this additional runway is the measure of distractibility. Male rats treated with amphetamine, 1 mg/kg, displayed an increase of the time spent in the additional runway. Baclofen, 2.5 and 5 mg/kg, and sodium valproate, 100 and 200 mg/kg, had no effect on distraction behavior when administered alone. However, when these drugs were administered together with amphetamine, 1 mg/kg, they completely inhibited the effects of the stimulant on distractibility. These data show that distractibility is similar to discrimination learning with regard to the capacity of GABAergic drugs to block the effects of dopaminergic stimulation. It is different from locomotor activity, however, where GABAergic drugs are ineffective in this respect.

Interactions between dopamine and GABA in the control of ambulatory activity

Ambulatory activity of male rats was quantified in an open field. The subjects were treated with DL-amphetamine and amfonelic acid alone or combined with the GABA transaminase inhibitors gamma-acetylen GABA (GAG) and sodium valproate as well as with the GABAA agonist THIP and the GABAB agonist baclofen. Subeffective doses of the GABAergic drugs did not modify the effects of moderate doses of the dopaminergic stimulants whereas effective doses continued to reduce ambulatory activity just as in the absence of dopaminergic activation. When DL-amphetamine or amfonelic acid were administered in doses that strongly enhanced ambulatory activity, doses of the GABAergic drugs that were inhibitory in the absence of dopaminergic stimulation were no longer effective. The mixed D1/D2 dopamine antagonist pimozide, the D1 antagonist SCH 23390 and the D2 antagonist sulpiride were then combined with subeffective doses of the GABA agonists. GAG, sodium valproate and baclofen were potentiated by pimozide and SCH 23390 but not by sulpiride. THIP was ineffective. These data show that GABAergic drugs had a reduced effect after stimulation of dopaminergic neurotransmission. On the other hand, when dopamine D1 receptors were blocked, nonselective GABA agonists and the GABAB agonist baclofen were potentiated. This was not the case for the GABAA agonist THIP, suggesting that the GABAA receptor is of slight importance for the interactions between GABA and dopamine in the control of ambulatory activity. No potentiation of GABAergic agonists was obtained after treatment with a dopamine D2 antagonist.

Neurochemical bases of locomotion and ethanol stimulant effects

The locomotor stimulant effect produced by alcohol (ethanol) is one of a large number of measurable ethanol effects. Ethanol-induced euphoria in humans and locomotor stimulation in rodents, a potential animal model of human euphoria, have long been recognized and the latter has been extensively characterized. Since the euphoria produced by ethanol may influence the development of uncontrolled or excessive alcohol use, a solid understanding of the neurochemical substrates underlying such effects is important. Such an understanding for spontaneous locomotion and for ethanol's stimulant effects is beginning to emerge. Herein we review what is known about three neurochemical substrates of locomotion and of ethanol's locomotor stimulant effects. Several lines of research have implicated dopaminergic, GABAergic, and glutamatergic neurotransmitter systems in determining these behaviors. A large collection of work is cited, which strongly implicates the above-mentioned neurotransmitter substances in the control of spontaneous locomotion. A smaller, but persuasive, body of evidence suggests that central nervous system processes utilizing these transmitters are involved in determining the effects of ethanol on locomotion. Particular emphasis has been placed on the mesolimbic ventral tegmental area to nucleus accumbens dopaminergic pathway, and on the ventral pallidum/substantia innominata, where GABA and glutamate have been found to play a role in altering the activity of this dopaminergic pathway. Research on ethanol and drug locomotor sensitization, increased responsiveness to the substance with repeated administration, is also reviewed as a process that may be important in the development of drug addiction.

Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety

tau-Vinyl GABA (vigabatrin, GVG) is a novel antiepileptic drug that irreversibly inhibits GABA transaminase and elevates GABA levels in all parts of the brain. In the present study, we investigated the anxiolytic and behavioral effects of GVG in the elevated plus-maze and the hole board compared to diazepam. Doses of 500 and 1,000 mg/kg GVG were injected IP to different groups of male Wistar rats and animals were tested either 4 or 24 h after injection. Animals administered diazepam (1.5 mg/kg, IP) and saline (1 ml) were tested 20 min after injection. GVG and diazepam were found to decrease significantly the number of squares visited and rearing; both had a suppressant effect on locomotor activity. Neither drug had an effect on exploration (head dipping). GVG at a dose of 1,000 mg/kg was shown to have a similar anxiolytic activity either after 4 or 24 h as diazepam, while GVG at 500 mg/kg did not show any significant anxiolytic effect.

GABA and behavior: the role of receptor subtypes

The discovery of different GABA receptor subtypes has stimulated research relating this neurotransmitter to a variety of behavioral functions and clinical disorders. The development of new and specific GABAergic compounds has made it possible to try to identify the specific functions of these receptors. The purpose of the present review is to evaluate the data regarding the functions of the GABA receptor subtypes in different behaviors such as motor function, reproduction, learning and memory, and aggressive-defensive behaviors. A description of GABAergic functions (stress, peripheral effects, thermoregulation) that might directly or indirectly affect behavior is also included. The possible involvement of GABA in different neurological and psychiatric disorders is also discussed. Although much research has been done trying to identify the possible role of GABA in different behaviors, the role of receptor subtypes has only recently attracted attention, and only preliminary data are available at present. It is therefore evident that still much work has to be done before a clear picture of the behavioral significance of these receptor subtypes can be obtained. Nevertheless, existing data are sufficient to justify the prediction that GABAergic agents, in the near future, will be much used in the field of behavioral pharmacology. It is hoped that the present review will contribute to this. Some specific suggestions concerning the most efficient way to pursue future research are also made.

Benzodiazepine receptor ligands and sexual behavior in the male rat: the role of GABAergic mechanisms

Diazepam and chlordiazepoxide produced a dose-dependent inhibition of ambulatory activity, motor execution and sexual behavior. The benzodiazepine antagonist flumazenil had no effect on these behaviors, while the inverse agonist FG 7142 inhibited sexual behavior without affecting motor functions. The GABA antagonist bicuculline was ineffective in all behavioral paradigms, while picrotoxin inhibited all behaviours. Picrotoxin blocked the motor effects of low doses of the benzodiazepines, but not those of higher doses. Neither did this drug block the effects of benzodiazepines on sexual behavior. Bicuculline was unable to block the effects of benzodiazepines on all behaviors. FG 7142, in a low dose, inhibited the effects of diazepam and chlordiazepoxide on ambulatory activity, but not their effects on motor execution or sexual behavior. The effects of the benzodiazepines and picrotoxin on sexual behavior could be a consequence of the motor impairment produced by these drugs, since the doses required to affect these two behaviors were similar. However, the fact that picrotoxin could block the motor deficiencies induced by the benzodiazepines without restoring sexual behavior suggests that these behavioral actions of the drugs can be differentiated. While some evidence was obtained suggesting a role of GABA in the motor effects of benzodiazepines, no evidence could be found for a role of GABA in their effects on sexual behavior.

Differential effects of chronic antidepressants in behavioural tests of beta-adrenergic and GABAB receptor function

The effects of chronic administration of anti-depressant drugs (28 days SC via Alzet 2ML4 osmotic minipumps) on the functional sensitivity of beta-adrenergic and GABA receptors have been assessed. Phenelzine (10 mg/kg), tranylcypromine (1 mg/kg), imipramine (30 mg/kg) and desmethylimipramine (10 mg/kg) attenuated the motor-suppressant effects of salbutamol (3 mg/kg) observed at 21-22 days of drug administration. No changes in the motor-suppressant effects of the GABA prodrug progabide (50 mg/kg) or the GABAB agonist (+/-)-baclofen (5 mg/kg) were induced by these antidepressants. These findings extend and confirm previous reports of functional changes in beta-adrenergic receptors but not of GABAB receptors following chronic antidepressant treatment.

Behavioral effects of GABA in the hippocampal formation: functional interaction with histamine

Some behavioral effects of GABA in the hippocampus and its probable interaction with histamine in adult male rats were studied. Four experiments were performed. In Expt. 1, rats were implanted unilaterally into the ventral hippocampus and they were microinjected with increasing doses of GABA. Five minutes later the following behavioral scores were measured in a holeboard: (1) locomotion, (2) head-dipping and (3) rearing. Results showed that GABA induced an increase in locomotion and a decrease in the frequency of long-lasting rears. In Expt. 2, the implanted rats were microinjected into the ventral hippocampus with Gamma-vinyl-GABA (GVG), an inhibitor of the metabolizing enzyme of GABA and picrotoxin and bicuculline, both antagonists of GABA. The following behaviors were measured later in the holeboard: (1) locomotion, (2) head-dipping frequency, (3) rearing activity and (4) grooming frequency. Results showed that GVG also increased the locomotor activity and this effect was antagonized by picrotoxin and bicuculline. In Expt. 3 the brain endogenous levels of GABA were measured in rats microinjected with GVG. Results showed that the GVG injection into the hippocampus augmented the endogenous levels of GABA. In Expt. 4 the implanted rats were microinjected into the hippocampus with GVG and histamine. Behavioral scores were measured later in the holeboard. Results showed that the increase in locomotion induced by GVG was blocked by the administration of histamine. Present results show that GABA may be involved in some hippocampal-mediated behaviors and suggest a histamine-GABA link in the final expression of these behaviors.

GABAergic drugs and lordosis behavior in the female rat

Agents modifying GABAergic neurotransmission were administered to ovariectomized rats treated with different doses of estradiol benzoate (EB) + progesterone (P) or with EB alone. Hormone treatments were designed to induce an intermediate level of receptivity in order to be able to observe both stimulatory and inhibitory effects on lordosis behavior. Both the GABAA receptor agonist THIP and the GABAB receptor agonist baclofen inhibited lordosis behavior at doses from 20 and 5 mg/kg, respectively. The GABA transaminase inhibitor gamma-acetylen GABA (GAG) and the GABA agonist 3-aminopropanesulfonic acid had no effects, even when high doses were administered. The GABAA receptor antagonist bicuculline had no effect by itself nor did it block the effects of THIP. It is therefore suggested that the GABAA receptor is of slight importance in the control of lordosis behavior. No evidence could be found supporting the hypothesis that an interaction between P and GABA is important for hormone-induced receptivity. It does not appear likely that motor disturbances are responsible for the inhibitory effects of baclofen and THIP. The exact mechanism by which these drugs inhibit lordosis behavior is not clear at present.

GABA receptors: are cellular differences reflected in function?

The putative involvement of GABAA and GABAB receptors in various behavioral and physiological effects is summarized in Table III. A division of function among the two types of GABA receptors appears to exist. GABAA receptors mediate feeding, cardiovascular regulation, anxiolytic effects, and anticonvulsive activity. GABAB receptors, on the other hand, are involved in analgesia, cardiovascular regulation, and depression. Although there is some overlap and shared functions among the receptor types, it is evident that GABAA and GABAB receptors have different behavioral and physiological profiles. Feeding, anticonvulsive activity and anxiety, for example, primarily involve GABAA receptors. Analgesia and depression, on the other hand, are GABAB effects. In those cases where GABAA and GABAB receptors mediate similar functions (e.g. cardiovascular regulation), they do so by affecting different transmitter systems and cellular mechanisms. It is proposed, therefore, that GABAA and GABAB receptors differ not only at the cellular level, but that they also have different functions in the mammalian central nervous system. The association of different subtypes of a receptor with different functions and mechanisms of action is not unique to the GABA system. D1 and D2 receptors in the dopamine system, for example, also exhibit some separation of function as do the mu, delta and kappa types of opiate receptors. Different subtypes of neurotransmitter receptors, therefore, appear to be a general organizing principle used by the brain to transduce chemical signals into different functional responses. A better understanding of the exact processes through which cellular signals are transformed into functional responses is a goal of future research.

Stereospecific actions of baclofen on sociosexual behavior, locomotor activity and motor execution

The behavior effects of racemic baclofen and the R and S enantiomers were studied in order to determine whether the stereospecificity found in receptor binding studies also applies to the behavioral actions of the drug. Racemic and R-baclofen inhibited sexual behavior, locomotor activity and motor execution at relatively low doses while s-baclofen was completely inactive even when a dose 40 times higher than the minimum effective dose of R-baclofen was used. The R enantiomer seems to be twice as active as racemic baclofen. These data strongly suggest that the behavioral effects of baclofen are the result of an action at the GABA-B receptor. In order to differentiate the effects of baclofen on sexual interactions from those on nonspecific social interactions, the sociosexual behavior was observed with a castrated male or a receptive female as stimulus animal. R, S-baclofen had effects only upon sociosexual interaction with a receptive female. Moreover, the inhibitory effects of baclofen were restricted to behavioral items related to sexual interactions, primarily those constituting precopulatory behaviors. Since no effect was observed in social interactions with a castrated male, it is suggested that the inhibition of sociosexual behavior is not a consequence of impairment of motor execution. Rather it appears that baclofen has a specific inhibitory effect on behaviors associated with the initiation of copulatory activity. Therefore, once initiated, sexual behavior was not significantly modified by baclofen.

Effect of ethanol on gamma-vinyl GABA-induced GABA accumulation in the substantia nigra and on synaptosomal GABA content in six rat brain regions

Two recently developed methods for estimating changes in presynaptic gamma-aminobutyric acid (GABA) homeostasis were used for the first time to evaluate the effects of acute and chronic ethanol treatments on GABA utilization. GABA accumulation in the left substantia nigra zona reticulata (SNR) following unilateral microinjection of gamma-vinyl GABA (GVG; 5 micrograms) was linear for at least 180 min while GABA concentrations in the uninjected right SNR did not change over this period. Net GABA accumulation (left minus right SNR) also increased linearly over this interval. Intraperitoneal (i.p.) administration of ethanol (0.3, 1 or 3 g/kg) 15 min after GVG microinjection did not significantly change either the rate of GABA accumulation in left SNR, the net GABA accumulated or the concentration of GABA in the uninjected right SNR relative to saline injected controls over the 45-min test interval. Likewise, GABA accumulation in the left SNR or steady-state GABA concentrations in the right SNR of chronically intoxicated rats or physically dependent animals withdrawn from ethanol for 12 h did not change significantly from that dextrose-fed controls. In a separate study, the effects of acute and chronic ethanol treatments on the concentration of GABA in synaptosomes isolated from the frontal cortex, hippocampus, tectum, striatum, cerebellum or brainstem were determined. Thirty min after acute treatment with ethanol (0.5, 1, 2 or 4 g/kg, i.p.) the concentration of GABA in synaptosomes from any of these brain regions was not significantly altered. Furthermore, chronic ethanol treatment sufficient to induce physical dependence and a severe ethanol withdrawal syndrome also did not significantly modify synaptosomal GABA concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Differential effects of ethyl (R,S)-nipecotate on the behaviors of highly and minimally aggressive female golden hamsters

The GABA uptake inhibitor ethyl (R,S)-nipecotate produces a dose-dependent suppression of aggression in highly aggressive hamsters but not in minimally aggressive ones. This suppression occurs at doses below those producing peripheral cholinergic effects; at the highest dose used it persists after these effects have dissipated. Doses sufficient to suppress aggression have no significant effect on grooming, locomotor activity and other behaviors but do affect sunflower seed acceptance. The differential effects of the drug on highly and minimally aggressive animals may indicate that their differences in aggression are due to differences in endogenous GABAergic activity. These results, together with previous evidence for parallel circadian variation in GABA uptake and aggressive behavior, suggest that GABA uptake may be an important endogenous regulator of aggression.

Interactions between naloxone and GABA in the control of locomotor activity in the rat

It was found that naloxone causes a small but significant reduction of motility. The GABAB agonist baclofen and the GABA transaminase inhibitor gamma-acetylenic GABA (GAG) also reduced locomotor activity. When a subeffective dose of baclofen was combined with naloxone 0.8 or 3.2 mg/kg, baclofen significantly inhibited motility beyond the inhibition caused by naloxone + saline. GAG, in a dose of 12.5 mg/kg, was also potentiated by naloxone, 3.2 mg/kg. The locomotion reducing effects of naloxone could be blocked by either picrotoxin or bicuculline. It is concluded that GABAergic mechanisms participate in the inhibition of locomotor activity provoked by naloxone. The possibility that this drug disinhibits GABAergic neurons is discussed.

GABAergic drugs and sexual behaviour in the male rat

The GABAA agonists 3-amino-1-propanesulfonic acid and THIP reduced sexual behaviour in male rats only at relatively high doses, whereas baclofen produced an almost complete inhibition at a low dose (2.5 mg/kg). The GABA transaminase inhibitor aminooxyacetic acid had no effects, while gamma-acetylenic GABA produced a slight inhibition of sexual behaviour. The GABAA antagonist bicuculline had no effect. When THIP was administered concurrently with bicuculline, the former drug was potentiated. Therefore it is concluded that the GABAA receptor is not responsible for the inhibitory actions of THIP, and since baclofen was the most potent drug with regard to effects on sexual behaviour, it is suggested that the GABAB rather than the GABAA receptor is involved in the control of that behaviour. The slight effects of the transaminase inhibitors and the lack of effect of bicuculline suggest that the GABAergic neurons participating in the control of sexual activity are not tonically active. Finally, data are presented showing that the effects of GABAergic drugs on sexual behaviour are probably independent from those on locomotor activity.